LONG MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 11:14:11 24/06/2024 pm IST | ||
| 8.19 EUR | -0.73% |
|
| Current month | -19.55% | ||
| 1 month | -20.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 8.19 | -0.73% |
| 20/24/20 | 8.25 | +4.83% |
| 19/24/19 | 7.87 | -3.79% |
| 18/24/18 | 8.18 | -1.33% |
| 17/24/17 | 8.29 | -4.16% |
Delayed Quote Deutsche Boerse AG
Last update June 24, 2024 at 11:14 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VF281B |
| ISIN | DE000VF281B3 |
| Date issued | 21/02/2019 |
| Strike | 1,175 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.41 € |
|---|---|
| Lowest since issue | 1.31 € |
| Spread | 0.72 € |
| Spread % | 8.32% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,805
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.51%
- Stock Market
- Certificates
- Certificat
